The Annals of Thoracic Surgery, Vol 30, 173-176, Copyright © 1980 by The Society of Thoracic Surgeons
Heterograft cardiac valve prostheses: a five-year follow-up
TM Grehl, JG Naifeh, J Broda, A Dajee and EJ Hurley
The major advance in the management of valvular heart disease over the past
twenty years has been due to prosthetic valve operation. The bioprostheses
have good hemodynamic function and a low rate of thromboembolism although
the long-term durability is unknown. In this series of 25 patients with 27
valves implanted over five years, there was an 9% early mortality and a 12%
late mortality. There have been no thromboembolic episodes. Primary
valvular dysfunction requiring operation occurred in 7.4% (2 out of 27).
All surviving patients are in New York Heart Association Functional Class I
or II.